Skip to main content

Table 3 Secondary symptom score endpoints SSS2-4, LSS2-4, and AUC-TSS1-10, ANCOVA-adjusted means, FAS

From: Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial

    I-C vs. placebo
  N Adjusteda mean (SE) Adjusteda mean (SE) differenceb 95 % CI p-value*
SSS2–4      
 I-C 98 1.12 (0.10) −0.18 (0.15) (-0.46, 0.11) 0.2310
 Placebo 97 1.30 (0.10)    
LSS2–4      
 I-C 98 4.66 (0.22) −0.44 (0.30) (-1.04, 0.16) 0.1465
 Placebo 97 5.10 (0.22)    
AUC-TSS1–10      
 I-C 98 41.94 (2.19) 0.73 (3.10) (-5.39, 6.85) 0.8148
 Placebo 97 41.21 (2.20)    
  1. CI confidence interval, SE standard error
  2. *For ANCOVA-adjusted comparison of placebo with I-C
  3. aThe means were adjusted for baseline SSS, LSS, or TSS
  4. bA negative treatment difference favored I-C